BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism

Cell Cycle

Volumn 12, Issue 3, 2013, Pages 452-462

  Boehm, Daniela ^a,b   Calvanese, Vincenzo ^a,b   Dar, Roy D ^a   Xing, Sifei ^d   Schroeder, Sebastian ^a,b   Martins, Laura ^e   Aull, Katherine ^a,c   Li, Pao Chen ^a,b   Planelles, Vicente ^e   Bradner, James E ^f   Zhou, Ming Ming ^g   Siliciano, Robert F ^d   Weinberger, Leor ^a,c   Verdin, Eric ^a,b   Ott, Melanie ^a,b  

^a GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

BRD2; BRD4; HIV; I BET; I BET151; JQ1; Latency; MS417; P TEFb; Tat

Indexed keywords

ANTIVIRUS AGENT; BET PROTEIN; BRD2 PROTEIN; BRD4 PROTEIN; HISTONE DEACETYLASE INHIBITOR; JQ 1; MEMBRANE PROTEIN; PROSTRATIN; SHORT HAIRPIN RNA; TRANSACTIVATOR PROTEIN; TRANSCRIPTION ELONGATION FACTOR; TRANSCRIPTION ELONGATION FACTOR TEFB; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VORINOSTAT;

ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SINGLE CELL TIME LAPSE FLUORESCENCE MICROSCOPY; TRANSCRIPTION ELONGATION; TRANSCRIPTION INITIATION; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS STRAIN;

EID: 84875525579     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.23309     Document Type: Article

References (74)

1. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5: 512-7; PMID:10229227; http://dx.doi.org/10.1038/8394
2. Sedaghat AR, Siliciano JD, Brennan TP, Wilke CO, Siliciano RF. Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART. PLoS Pathog 2007; 3:e122; PMID:17784786; http://dx.doi.org/10.1371/journal. ppat.0030122
3. Geeraert L, Kraus G, Pomerantz Rj.Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu Rev Med 2008; 59: 487-501; PMID:17845138; http://dx.doi.org/10.1146/annurev.med.59.062806.123001
4. Williams SA, Chen LF, Kwon H, Fenard D, Bisgrove D, Verdin E, et al. Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem 2004; 279: 42008-17; PMID:15284245; http://dx.doi.org/10.1074/jbc. M402124200
5. Xing S, Bullen CK, Shroff NS, Shan L, Yang HC, Manucci JL, et al. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol 2011; 85: 6060-4; PMID:21471244; http://dx.doi.org/10.1128/JVI.02033-10
6. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 2009; 25: 207-12; PMID:19239360; http://dx.doi.org/10.1089/aid.2008.0191
7. Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, Martin J, et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 2009; 284: 6782-9; PMID:19136668; http://dx.doi.org/10.1074/jbc. M807898200
8. Edelstein LC, Micheva-Viteva S, Phelan BD, Dougherty JP. Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res Hum Retroviruses 2009; 25: 883-7; PMID:19689202; http://dx.doi.org/10.1089/aid.2008.0294
9. Van Lint C, Emiliani S, Ott M, Verdin E. Transcriptional activation of the HIV-1 promoter in response to histone acetylation. EMBO J 1996; 15: 1112-20. PMID: 8605881
10. Quivy V, Adam E, Collette Y, Demonte D, Chariot A, Vanhulle C, et al. Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies. J Virol 2002; 76: 11091-103; PMID:12368351; http://dx.doi .org/10.1128/JVI.76.21.11091-11103.2002
11. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010; 468: 1119-23; PMID:21068722; http://dx.doi.org/10.1038/nature09589
12. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature 2010; 468: 1067-73; PMID:20871596; http://dx.doi.org/10.1038/nature09504
13. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011; 478: 529-33; PMID:21964340; http://dx.doi.org/10.1038/nature10509
14. Wu SY, Chiang CM. The double bromodomaincontaining chromatin adaptor Brd4 and transcriptional regulation. J Biol Chem 2007; 282: 13141-5; PMID:17329240; http://dx.doi.org/10.1074/jbc. R700001200
15. Yang Z, Yik JH, Chen R, He N, Jang MK, Ozato K, et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell 2005; 19: 535-45; PMID:16109377; http://dx.doi.org/10.1016/j. molcel.2005.06.029
16. Jang MK, Mochizuki K, Zhou M, Jeong HS, Brady JN, Ozato K. The bromodomain protein BRD4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transactivation. Mol Cell. 2005;19: 523-34. PMID:16109376
17. Zhu Y, Pe'ery T, Peng J, Ramanathan Y, Marshall N, Marshall T, et al. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev 1997; 11: 2622-32; PMID:9334325; http://dx.doi.org/10.1101/ gad.11.20.2622
18. Peterlin BM, Price DH. Controlling the elongation phase of transcription with P-TEFb. Mol Cell 2006; 23: 297-305; PMID:16885020; http://dx.doi.org/10. 1016/j.molcel.2006.06.014
19. Yamaguchi Y, Takagi T, Wada T, Yano K, Furuya A, Sugimoto S, et al. NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. Cell 1999; 97: 41-51; PMID:10199401; http://dx.doi.org/10.1016/S0092-8674(00)80713-8
20. Wada T, Takagi T, Yamaguchi Y, Ferdous A, Imai T, Hirose S, et al. DSIF, a novel transcription elongation factor that regulates RNA polymerase II processivity, is composed of human Spt4 and Spt5 homologs. Genes Dev 1998; 12: 343-56; PMID:9450929; http://dx.doi.org/10.1101/gad.12.3.343
21. Wada T, Takagi T, Yamaguchi Y, Watanabe D, Handa H. Evidence that P-TEFb alleviates the negative effect of DSIF on RNA polymerase II-dependent transcription in vitro. EMBO J 1998; 17: 7395-403; PMID:9857195; http://dx.doi.org/10.1093/emboj/17.24.7395
22. Price DH. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol 2000; 20: 2629-34; PMID:10733565; http://dx.doi.org/10.1128/MCB.20.8.2629-2634.2000
23. Wei P, Garber ME, Fang SM, Fischer WH, Jones KA. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loopspecific binding to TAR RNA. Cell 1998; 92: 451-62; PMID:9491887; http://dx.doi.org/10.1016/S0092-8674(00)80939-3
24. Mueller D, Bach C, Zeisig D, Garcia-Cuellar MP, Monroe S, Sreekumar A, et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification Blood 2007; 110: 4445-4454; PMID: 17855633 http://dx.doi.org/10.1182/blood- 2007-05-090514
25. Yik JH, Chen R, Nishimura R, Jennings JL, Link AJ, Zhou Q. Inhibition of p-TEFb (CDK9/Cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA. Mol Cell 2003; 12: 971-82. PMID:14580347
26. Michels AA, Fraldi A, Li Q, Adamson TE, Bonnet F, Nguyen VT, et al. Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb (CDK9/cyclin T) inhibitor. EMBO J 2004; 23: 2608-19; PMID:15201869; http://dx.doi.org/10.1038/ sj.emboj.7600275
27. Bisgrove DA, Mahmoudi T, Henklein P, Verdin E. Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proc Natl Acad Sci USA 2007; 104: 13690-5; PMID:17690245; http://dx.doi.org/10.1073/pnas. 0705053104
28. Bisgrove D, Lewinski M, Bushman F, Verdin E. Molecular mechanisms of HIV-1 proviral latency. Expert Rev Anti Infect Ther 2005; 3: 805-14; PMID:16207172; http://dx.doi.org/10.1586/14787210.3.5.805
29. Fu J, Yoon HG, Qin J, Wong j.Regulation of P-TEFb Elongation Complex Activity by CDK9 Acetylation. Mol. Cell. Biol 2007; 27: 4641-51 http://dx.doi.org/10.1128/MCB.00857-06
30. Cho S, Schroeder S, Kaehlcke K, Kwon HS, Pedal A, Herker E, et al. Acetylation of cyclin T1 regulates the equilibrium between active and inactive P-TEFb in cells. EMBO J 2009; 28: 1407-17; PMID:19387490; http://dx.doi.org/10. 1038/emboj.2009.99
31. Ott M, Schnölzer M, Garnica J, Fischle W, Emiliani S, Rackwitz HR, et al. Acetylation of the HIV-1 Tat protein by p300 is important for its transcriptional activity. Curr Biol 1999; 9: 1489-92; PMID:10607594; http://dx.doi.org/10.1016/S0960-9822(00)80120-7
32. Kiernan RE, Vanhulle C, Schiltz L, Adam E, Xiao H, Maudoux F, et al. HIV-1 tat transcriptional activity is regulated by acetylation. EMBO J 1999; 18: 6106-18; PMID:10545121; http://dx.doi.org/10.1093/emboj/18.21.6106
33. Dorr A, Kiermer V, Pedal A, Rackwitz HR, Henklein P, Schubert U, et al. Transcriptional synergy between Tat and PCAF is dependent on the binding of acetylated Tat to the PCAF bromodomain. EMBO J 2002; 21: 2715-23; PMID:12032084; http://dx.doi.org/10.1093/emboj/21.11.2715
34. Mujtaba S, He Y, Zeng L, Farooq A, Carlson JE, Ott M, et al. Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF bromodomain. Mol Cell 2002; 9: 575-86; PMID:11931765; http://dx.doi.org/10.1016/S1097-2765(02)00483-5
35. Kaehlcke K, Dorr A, Hetzer-Egger C, Kiermer V, Henklein P, Schnoelzer M, et al. Acetylation of Tat defines a cyclinT1-independent step in HIV transactivation. Mol Cell 2003; 12: 167-76; PMID:12887902; http://dx.doi.org/10. 1016/S1097-2765(03)00245-4
36. Brès V, Tagami H, Péloponèse JM, Loret E, Jeang KT, Nakatani Yet al. Differential acetylation of Tat coordinates its interaction with the co-activators cyclin T1 and PCAF. EMBO J 2002; 21: 6811-9
37. Schröder S, Cho S, Zeng L, Zhang Q, Kaehlcke K, Mak L, et al. Two-pronged binding with bromodomain- containing protein 4 liberates positive transcription elongation factor b from inactive ribonucleoprotein complexes. J Biol Chem 2012; 287: 1090-9; PMID:22084242; http://dx.doi.org/10.1074/jbc. M111.282855
38. Zhang G, Liu R, Zhong Y, Plotnikov AN, Zhang W, Zeng L, et al. Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J Biol Chem 2012; 287: 28840-51; PMID:22645123; http://dx.doi.org/10.1074/jbc. M112.359505
39. Banerjee C, Archin N, Michaels D, Belkina AC, Denis GV, Bradner J, et al. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol 2012; 92: 1147-54; PMID:22802445; http://dx.doi.org/10.1189/jlb. 0312165
40. Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012; 120: 2843-52; PMID:22904298; http://dx.doi.org/10.1182/blood-2012-02-413021
41. Bartholomeeusen K, Xiang Y, Fujinaga K, Peterlin BM. Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. J Biol Chem 2012; 287: 36609-16; PMID:22952229; http://dx.doi.org/10.1074/jbc.M112.410746
42. Li Z, Guo J, Wu Y, Zhou Q. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res 2013; 41: 277-87; PMID:23087374; http://dx.doi.org/10.1093/nar/gks976
43. Zhu J, Gaiha GD, John SP, Pertel T, Chin CR, Gao G, et al. Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep 2012; 2: 807-16; PMID:23041316; http://dx.doi.org/10.1016/j.celrep.2012.09.008
44. Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 2003; 22: 1868-77; PMID:12682019; http://dx.doi.org/10.1093/emboj/cdg188
45. Kutsch O, Benveniste EN, Shaw GM, Levy DN. Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J Virol 2002; 76: 8776-86; PMID:12163598; http://dx.doi.org/10.1128/ JVI.76.17.8776-8786.2002
46. Xing S, Bhat S, Shroff NS, Zhang H, Lopez JA, Margolick JB, et al. Novel structurally related compounds reactivate latent HIV-1 in a bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Antimicrob Chemother 2012; 67: 398-403; PMID:22160146; http://dx.doi.org/10. 1093/jac/dkr496
47. Yang HC, Xing S, Shan L, O'Connell K, Dinoso J, Shen A, et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 2009; 119: 3473-86; PMID:19805909
48. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012; 36: 491-501; PMID:22406268; http://dx.doi.org/10.1016/j.immuni.2012.01.014
49. Bosque A, Planelles V. Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells. Methods 2011; 53: 54-61; PMID:20970502; http://dx.doi.org/10.1016/j.ymeth.2010.10.002
50. Bosque A, Planelles V. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 2009; 113: 58-65; PMID:18849485; http://dx.doi.org/10.1182/blood-2008-07-168393
51. Dar RD, Razooky BS, Singh A, Trimeloni TV, McCollum JM, Cox CD, et al. Transcriptional burst frequency and burst size are equally modulated across the human genome. Proc Natl Acad Sci USA 2012; 109: 17454-9; PMID:23064634; http://dx.doi.org/10.1073/pnas.1213530109
52. Kepler TB, Elston TC. Stochasticity in transcriptional regulation: origins, consequences, and mathematical representations. Biophys J 2001; 81: 3116-36; PMID:11720979; http://dx.doi.org/10.1016/S0006-3495(01)75949-8
53. Simpson ML, Cox CD, Sayler GS. Frequency domain chemical Langevin analysis of stochasticity in gene transcriptional regulation. J Theor Biol 2004; 229: 383-94; PMID:15234205; http://dx.doi.org/10.1016/j.jtbi.2004.04.017
54. Singh A, Razooky B, Cox CD, Simpson ML, Weinberger LS. Transcriptional bursting from the HIV-1 promoter is a significant source of stochastic noise in HIV-1 gene expression. Biophys J 2010; 98:L32-4; PMID:20409455; http://dx.doi.org/10.1016/j.bpj.2010.03.001
55. Malovannaya A, Lanz RB, Jung SY, Bulynko Y, Le NT, Chan DW, et al. Analysis of the human endogenous coregulator complexome. Cell 2011; 145: 787-99; PMID:21620140; http://dx.doi.org/10.1016/j.cell.2011.05.006
56. Emiliani S, Fischle W, Ott M, Van Lint C, Amella CA, Verdin E. Mutations in the tat Gene Are Responsible for Human Immunodeficiency Virus Type 1 Postintegration Latency in the U1 Cell Line. J Virol. 1998; 72: 1666-70. PMID:9445075
57. Emiliani S, Van Lint C, Fischle W, Paras P Jr, Ott M, Brady J, Verdin E. A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency. Proc Natl Acad Sci USA. 1996; 93: 6377-81. PMID:8692823
58. Antoni BA, Rabson AB, Kinter A, Bodkin M, Poli G.NF-kappa B-dependent and -independent pathways of HIV activation in a chronically infected T cell line. Virology 1994; 202: 684-94; PMID:7913275; http://dx.doi.org/10.1006/viro.1994. 1390
59. Denis GV, McComb ME, Faller DV, Sinha A, Romesser PB, Costello CE. Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines. J Proteome Res 2006; 5: 502-11; PMID:16512664; http://dx.doi.org/10.1021/pr050430u
60. Denis GV, Vaziri C, Guo N, Faller DV. RING3 kinase transactivates promoters of cell cycle regulatory genes through E2F. Cell Growth Differ 2000; 11: 417-24; PMID:10965846
61. LeRoy G, Rickards B, Flint Sj.The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription. Mol Cell 2008; 30: 51-60; PMID:18406326; http://dx.doi.org/10.1016/j.molcel. 2008.01.018
62. Sinha A, Faller DV, Denis GV. Bromodomain analysis of Brd2-dependent transcriptional activation of cyclin A. Biochem J 2005; 387: 257-69; PMID:15548137; http://dx.doi.org/10.1042/BJ20041793
63. Peng J, Dong W, Chen L, Zou T, Qi Y, Liu Y. Brd2 is a TBP-associated protein and recruits TBP into E2F-1 transcriptional complex in response to serum stimulation. Mol Cell Biochem 2007; 294: 45-54; PMID:17111193; http://dx.doi.org/10.1007/s11010-006-9223-6
64. Benevolenskaya EV, Murray HL, Branton P, Young RA, Kaelin WG Jr. Binding of pRB to the PHD protein RBP2 promotes cellular differentiation. Mol Cell 2005; 18: 623-35; PMID:15949438; http://dx.doi.org/10.1016/j.molcel.2005.05.012
65. Jiang YW, Veschambre P, Erdjument-Bromage H, Tempst P, Conaway JW, Conaway RC, et al. Mammalian mediator of transcriptional regulation and its possible role as an end-point of signal transduction pathways. Proc Natl Acad Sci USA 1998; 95: 8538-43; PMID:9671713; http://dx.doi.org/10.1073/pnas.95.15. 8538
66. Kuras L, Borggrefe T, Kornberg RD. Association of the Mediator complex with enhancers of active genes. Proc Natl Acad Sci USA 2003; 100: 13887-91; PMID:14623974; http://dx.doi.org/10.1073/pnas.2036346100
67. Kornberg RD. Mediator and the mechanism of transcriptional activation. Trends Biochem Sci 2005; 30: 235-9; PMID:15896740; http://dx.doi.org/10.1016/j. tibs.2005.03.011
68. Belkina AC, Denis GV. BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer 2012; 12: 465-77; PMID:22722403; http://dx.doi.org/ 10.1038/nrc3256
69. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-7; PMID:8602510; http://dx.doi.org/10.1126/ science.272.5259.263
70. Weinberger LS, Burnett JC, Toettcher JE, Arkin AP, Schaffer DV. Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell 2005; 122: 169-82; PMID:16051143; http://dx.doi.org/10.1016/j.cell.2005.06.006
71. Weinberger LS, Shenk T. An HIV feedback resistor: auto-regulatory circuit deactivator and noise buffer. PLoS Biol 2007; 5:e9; PMID:17194214; http://dx.doi.org/10.1371/journal.pbio.0050009
72. Weinberger LS, Dar RD, Simpson ML. Transientmediated fate determination in a transcriptional circuit of HIV. Nat Genet 2008; 40: 466-70; PMID:18344999; http://dx.doi.org/10.1038/ng.116
73. Austin DW, Allen MS, McCollum JM, Dar RD, Wilgus JR, Sayler GS, et al. Gene network shaping of inherent noise spectra. Nature 2006; 439: 608-11; PMID:16452980; http://dx.doi.org/10.1038/nature04194
74. Cox CD, McCollum JM, Allen MS, Dar RD, Simpson ML. Using noise to probe and characterize gene circuits. Proc Natl Acad Sci USA 2008; 105: 10809-14; PMID:18669661; http://dx.doi.org/10.1073/pnas.0804829105